6 completed, 5 not yet recruiting, 3 terminated, 3 withdrawn. 10 Phase 2, 4 Phase 1, 4 Phase 3, 2 Not applicable.
Follow Hydroxychloroquine (HCQ): new trials by email Literature Review of Hydroxychloroquine (HCQ) trials Research Report on Hydroxychloroquine (HCQ)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months. Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone - Rheumatic Fever, Rheumatic Heart Disease in Children | Phase 3 | Not yet recruiting | Starship Child Health, Te Toka Tumai Auckland | 600 | 2026-12-01 | 2026-10-07 |
| Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children rituximab, Mycophenolate Mofetil (MMF) Treatment, Cyclophosphamide - Lupus Nephritis | Not applicable | Not yet recruiting | Nanfang Hospital, Southern Medical University | 112 | 2026-06-01 | 2026-06-30 |
| The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial) Hydroxychloroquine (HCQ), Methotrexate (MTX) - Frontal Fibrosing Alopecia, Cicatricial Alopecia | Not yet recruiting | Erasmus Medical Center | 50 | 2025-11-01 | 2025-09-29 | |
| Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome Upadacitinib (ABT-494), Hydroxychloroquine (HCQ) - Primary Sjögren's Syndrome (pSS) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 30 | 2025-03-10 | 2025-03-11 |
| A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease Hydroxychloroquine (HCQ) - Parkinson&Amp;#39;s Disease | Phase 2 | Not yet recruiting | Ottawa Hospital Research Institute | 40 | 2025-03-01 | 2025-02-10 |
| Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 Hydroxychloroquine (HCQ), Standard care, Placebo - Covid19, COVID-19 Prevention | Phase 3 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 1000 | 2021-03-22 | 2021-06-11 |
| Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 Hydroxychloroquine (HCQ), Azithromycin (Azithro), Placebo for Hydroxychloroquine - COVID-19, SARS-CoV 2 | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2020-05-13 | 2021-11-16 |
| Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals Hydroxychloroquine (HCQ), Placebo oral tablet - COVID19, Sars-CoV2 | Phase 3 | Withdrawn | Abderrahmane Mami Hospital | 2020-04-28 | 2020-08-28 | |
| Treating COVID-19 With Hydroxychloroquine (TEACH) Hydroxychloroquine (HCQ), Placebo: Calcium citrate - COVID-19 | Phase 2 | Terminated | NYU Langone Health | 128 | 2020-04-15 | 2022-04-22 |
| Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients Hydroxychloroquine (HCQ) - Sars-CoV2 | Phase 3 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 7 | 2020-04-03 | 2020-09-07 |
| COVID-19 PrEP HCW HCQ Study Hydroxychloroquine (HCQ) - COVID-19 | Phase 2 | Completed | NYU Langone Health | 130 | 2020-04-03 | 2022-12-14 |
| Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") Hydroxychloroquine (HCQ), Gedatolisib - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Abramson Cancer Center at Penn Medicine | 2019-02-26 | 2020-04-28 | |
| Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer Sorafenib (SOR), Hydroxychloroquine (HCQ) - Hepatocellular Cancer | Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 37 | 2017-02-16 | 2026-10-21 |
| Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss Hydroxychloroquine (HCQ), Placebo - Recurrent Pregnancy Loss, Miscarriage | Phase 2 | Withdrawn | University of Utah | 2016-07-01 | 2016-08-12 | |
| Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma Trametinib 2 mg daily, hydroxychloroquine (HCQ), dabrafenib 150 mg orally twice a day - Advanced BRAF Mutant Melanoma | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 50 | 2014-10-01 | 2022-01-20 |
| Inducing Immune Quiescence to Prevent HIV Infection in Women Acetylsalicylic Acid (ASA), Hydroxychloroquine (HCQ) - HIV | Not applicable | Completed | University of Manitoba | 91 | 2014-04-01 | 2019-10-10 |
| A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma Hydroxychloroquine (HCQ), Vemurafenib (VEM) - Melanoma | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 8 | 2013-06-01 | 2020-05-29 |
| A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer Hydroxychloroquine (HCQ), Gemcitabine, Abraxane - Advanced Adenocarcinoma, Metastatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 119 | 2011-12-01 | 2025-07-25 |
COVID-19 (6) · Abortion, Spontaneous (1) · Adenocarcinoma (1) · Alopecia (1) · Breast Neoplasms (1) · Hair Diseases (1) · Liver Neoplasms (1) · Lupus Nephritis (1) · Melanoma (1) · Neuroinflammatory Diseases (1) · Rheumatic Fever (1) · Rheumatic Heart Disease (1)
Abramson Cancer Center at Penn Medicine (4) · NYU Langone Health (2) · Abderrahmane Mami Hospital (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Erasmus Medical Center (1) · Nanfang Hospital, Southern Medical University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Ottawa Hospital Research Institute (1) · Peking University People's Hospital (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Starship Child Health, Te Toka Tumai Auckland (1) · The University of Texas Health Science Center at San Antonio (1) · University of Manitoba (1) · University of Utah (1)
United States (9) · Australia (1) · Canada (1) · China (1) · France (1) · India (1) · Kenya (1) · Netherlands (1) · New Zealand (1) · Tunisia (1)
Ravi Amaravadi, MD (2) · Angela DeMichele, MD (1) · Davey Smith, MD (1) · David Grimes, MD, FRCPC (1) · H. Michael Belmont, MD (1) · Jalila Ben Khelil, Pr (1) · Jing He (1) · Keith R. Fowke, PhD (1) · Mark Mulligan, MD, FIDSA (1) · Peter O'Dwyer, MD (1) · Robert Silver, MD (1) · Sukeshi Patel Arora, MD (1)